Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) news covers the company’s progress as a biopharmaceutical issuer focused on therapies for autoimmune diseases with high unmet medical needs. Investors and followers of AUPH can use this page to review company‑issued updates, financial announcements and clinical data disclosures that shape the outlook for its products and pipeline.
News releases from Aurinia frequently highlight commercial performance and medical data for LUPKYNIS (voclosporin), which the company describes as the first FDA‑approved oral therapy for adult patients with active lupus nephritis. Regular quarterly earnings announcements detail trends in net product sales of LUPKYNIS, license, collaboration and royalty revenue, net income and cash flows. These updates are often accompanied by guidance ranges for total revenue and net product sales, as well as information on the company’s share repurchase plan.
In addition to financial results, Aurinia’s news flow includes clinical and scientific milestones. The company has reported post‑hoc analyses from the AURORA 1 trial, real‑world data from the ENLIGHT‑LN registry and new mechanistic findings on voclosporin, often presented at major rheumatology and nephrology meetings. Separate announcements describe progress with aritinercept (AUR200), a dual BAFF and APRIL inhibitor, including Phase 1 study results and plans for further clinical development in autoimmune diseases.
Visitors to this AUPH news page can review a stream of earnings releases, pipeline updates, medical conference presentations and regulatory‑related communications drawn from company press releases and SEC‑referenced materials. This provides a centralized view of how Aurinia communicates its commercial performance, clinical findings and strategic steps in autoimmune disease drug development.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced an interim analysis of its AURORA 2 study, to be presented at the EULAR 2021 Congress from June 2-5, 2021. This analysis involved 216 subjects who transitioned from the Phase 3 AURORA study and demonstrated sustained reductions in proteinuria without affecting renal function over 104 weeks. The voclosporin treatment showed a greater reduction in urine protein creatinine ratio compared to controls. This data reinforces the clinical efficacy of LUPKYNIS, the first FDA-approved oral treatment for lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in two upcoming investor conferences. The RBC Capital Markets Global Healthcare Conference is scheduled for May 19, 2021, at 10:55 a.m. ET, followed by the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 10:45 a.m. ET. Interested parties can access the live audio webcast via the Investors section on Aurinia's website, with a replay available afterward. Aurinia focuses on delivering therapies for serious diseases, including LUPKYNIS™, the first FDA-approved oral treatment for active lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced its commitment to improving healthcare access for individuals affected by systemic lupus erythematosus (SLE) and lupus nephritis (LN), coinciding with World Lupus Day. The company is sponsoring grants to establish patient navigator programs aimed at underserved communities, particularly Black, Asian, and Hispanic populations disproportionately affected by LN. As the COVID-19 pandemic has hindered healthcare access, these programs are crucial for connecting patients to necessary resources and education. Organizations can apply for grants until June 1, 2021.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the publication of Phase 3 AURORA 1 study results for LUPKYNIS (voclosporin) in treating lupus nephritis (LN). The study, published in The Lancet, demonstrated that LUPKYNIS combined with mycophenolate mofetil (MMF) and low-dose corticosteroids achieved a complete renal response rate of 41% at 52 weeks, significantly outpacing the 23% in the control group. Additionally, LUPKYNIS was well-tolerated, showing a comparable safety profile to the standard treatment. FDA approved LUPKYNIS in January 2021.
Aurinia Pharmaceuticals reported its financial results for Q1 2021, with revenues of $0.9 million attributed to the launch of LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis. The company experienced a net loss of $50.4 million or $0.40 per share, up from a $25.9 million loss in Q1 2020. Operating cash decreased to $360.9 million due to commercial infrastructure investments. Aurinia anticipates improved market access as healthcare facilities reopen. Upcoming milestones include EMA filing and new clinical trials.
Aurinia Pharmaceuticals will release its Q1 2021 financial results on May 6, 2021, after market closure. A conference call is scheduled for the same day at 5:00 p.m. EDT to discuss the results and provide a business update. The call can be accessed via dial-in or through an audio webcast available on the company's website. Aurinia focuses on serious diseases, having introduced LUPKYNIS™, the first FDA-approved oral therapy for adult patients with active lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation of its executive management team in a fireside chat at the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 2:30 p.m. ET. Interested individuals can access the live audio webcast through the 'News/Events' section on Aurinia's corporate website. A replay will also be available. Aurinia focuses on therapies for serious diseases, having launched LUPKYNIS™ (voclosporin), the first FDA-approved oral treatment for active lupus nephritis in adults.
Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS (voclosporin) for lupus nephritis (LN) at the NKF 2021 Spring Clinical Meetings. The pooled data from 532 patients showed significant treatment benefits in complete renal response (CRR) for LUPKYNIS compared to placebo across various biopsy class subgroups. LUPKYNIS, the first FDA-approved oral treatment for adult LN, offers a dual mechanism of action and is designed to improve outcomes in patients with this serious condition.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced a favorable assessment of LUPKYNIS™ (voclosporin) by the Institute for Clinical and Economic Review (ICER). The report, dated March 12, 2021, states LUPKYNIS is a cost-effective treatment for lupus nephritis (LN), particularly for African American patients. In clinical trials, LUPKYNIS nearly doubled complete response rates compared to standard therapy. ICER highlighted the drug's potential to reduce healthcare disparities. CEO Peter Greenleaf expressed optimism about LUPKYNIS' real-world value for patients and the healthcare system.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in three upcoming investor conferences. The events include the Cowen 41st Annual Healthcare Conference on March 4, 2021, at 2:10 p.m. ET, the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 10:40 a.m. ET. Interested investors can access the live webcasts through the 'Investors' section on Aurinia's website. Aurinia specializes in therapies for serious diseases, notably the FDA-approved LUPKYNIS™ for lupus nephritis.